Epigenetic modifications, such as DNA methylation, can lead to or complicate disease, and lead to worse patient outcomes. Speaking from the Myeloma 2017 meeting in Edinburgh, UK, Benjamin Barwick, MD, of Emory University, Atlanta, GA, outlines how these alterations could be explored in terms of targeting them for multiple myeloma (MM) therapies. Dr Barwick highlights the potential to perform clinical trials for MM treatment with approved drugs that target DNA methylation in myelodysplastic syndromes and leukemia.
Targeting DNA methylation as a therapeutic target in multiple myeloma
